Results 61 to 70 of about 1,710,059 (263)

Frequency of polymorphisms in the IKZF1 and CDKN2A/2B genes and descriptive analysis in pediatric patients with acute lymphoblastic leukemia: a multicenter hospital-based prevalence study in Rio De Janeiro

BMC Cancer
Background Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and B-cell ALL (B-ALL) is the most common subtype. The understanding of ALL has advanced significantly in recent years due to genomic sequencing, which has made it ...
Ariadne da Rocha Figueiredo, Thayana da Conceição Barbosa, Mariana Emerenciano, Marcelo Gerardin Poirot Land   +3 more
doaj   +1 more source

Disease and treatment burden in patients with leukaemia: family members/partner perspective

Frontiers in Hematology
BackgroundLeukaemia patients require comprehensive care, including treatment, hospital visits, and family support. An awareness of the impact of leukaemia on family members is crucial. The Acute Leukemia Advocates Network, Chronic Lymphoid Leukemia (CLL)
Esther Natalie Oliva, Tatyana Ionova, Samantha Nier, Zack Pemberton-Whiteley, Zack Pemberton-Whiteley, Nick York, Denis Costello, Sam Salek   +7 more
doaj   +1 more source

RNA INTERFERENCE (RNAI): AN EFFECTIVE WAY TO DEVELOP RATIONAL COMBINATION THERAPIES WITH HYPOMETHYLATING AGENTS IN ACUTE LEUKAEMIAS AND MYELODYSPLASTIC SYNDROME [PDF]

European Medical Journal Hematology, 2013
Therapeutic progress in aggressive myeloid malignancies such as acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS) and advanced myeloproliferative neoplasm (MPNs) has been slow.
Raoul Tibes
doaj  

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

Molecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim, Maryam Aslam, Elouise Torruella, Alphons Sony, Asif Rahman, Simira Smith, Columba de la Parra, Moira Sauane   +7 more
wiley   +1 more source

Regulation of the lncRNA NEAT1 by p53‐ΔNp63 crosstalk modulates the DNA damage response and therapeutic efficacy in HNSCC

Molecular Oncology, EarlyView.
In head and neck squamous cell carcinoma (HNSCC) p53 and p63 exert opposite roles on the transcription regulation of the lncRNA NEAT1. Under basal conditions, p53 levels are low and p63 represses NEAT1 expression. Upon genotoxic stress, p53 is rapidly induced, displacing p63 from the NEAT1 promoter leading to NEAT1 transcriptional activation and ...
Sara De Domenico, Veronica La Banca, Silvia D'Amico, Stefano Scalera, Sara Nicolai, Angelo Peschiaroli   +5 more
wiley   +1 more source

Signaling through CD44 affects cell cycle progression and c-Jun expression in acute myeloid leukemia cells [PDF]

, 2004
We present here the first evidence linking CD44 signaling to c-Jun expression and cell cycle progression in myeloid cell line models. CD44 ligation with the anti-CD44 monoclonal antibodies have been shown to induce differentiation and inhibit the ...
Abdul Ali Peer Zada, Peer Zada, Abdul Ali   +1 more
core   +1 more source

Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria

Haematologica, 2010
Background Mixed phenotype acute leukemia (MPAL) represents a diagnostic and therapeutic dilemma. The European Group for the Immunological Classification of Leukemias (EGIL) scoring system unambiguously defines MPAL expressing aberrant lineage markers ...
Ester Mejstrikova, Jana Volejnikova, Eva Fronkova, Katerina Zdrahalova, Tomas Kalina, Jaroslav Sterba, Yahia Jabali, Vladimir Mihal, Bohumir Blazek, Zdena Cerna, Daniela Prochazkova, Jiri Hak, Zuzana Zemanova, Marie Jarosova, Alexandra Oltova, Petr Sedlacek, Jiri Schwarz, Jan Zuna, Jan Trka, Jan Stary, Ondrej Hrusak   +20 more
doaj   +1 more source

Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin

, 2018
Deferasirox (DFX), in addition to its iron-chelation property, has marked anti-proliferative effects on cancer cells. However, the activity and mechanism by which DFX inhibits acute myeloid leukemia (AML) cells remain to be elucidated.
Huang, Yu-Ting, Lin, Chaio-Lin, Lin, Hsin-Ting, Feng, Chiu-Che, Lo, Wen-Jyi, Chang, Yu-Chien, 鄭旭辰, Cheng, Hsu-Chen, Yeh, Su-Peng   +8 more
core   +1 more source

A novel self-lipid antigen targets human T cells against CD1c(+) leukemias [PDF]

, 2014
T cells that recognize self-lipids presented by CD1c are frequent in the peripheral blood of healthy individuals and kill transformed hematopoietic cells, but little is known about their antigen specificity and potential antileukemia effects.
Lepore, Marco, Locatelli, Franco, Giulia Casorati, Paul Jenö, Chengfeng Xia, Consonni, Michela, S. R. Gundimeda, P. Jeno, Daniela Montagna, C. Bonini, Alessandra Forcina, G. Casorati, Claudia de Lalla, Franco Locatelli, Sansano, Sebastiano, Bonini, Chiara, Piccolo, Francesco, Xia, Chengfeng, Z. Li, P. Dellabona, Garavaglia, Claudio, H. Gsellinger, F. Piccolo, de Lalla, Claudia, Paolo Dellabona, G. Ni, F. Ciceri, Gundimeda, S. Ramanjaneyulu, Heiko Gsellinger, Häussinger, Daniel, Daniel Häussinger, Scelfo, Andrea, L. Mori, C. Garavaglia, Gennaro De Libero, A. Bondanza, Michela Consonni, Sebastiano Sansano, A. Forcina, Ciceri, Fabio, Jenö, Paul, Fabio Ciceri, M. Lepore, Attilio Bondanza, Gsellinger, Heiko, De Libero, Gennaro, S. Sansano, Bondanza, Attilio, Casorati, Giulia, D. Haussinger, Marco Lepore, C. de Lalla, G. De Libero, M. Consonni, Guanghui Ni, Lucia Mori, Li, Zhiyuan, Zhiyuan Li, Montagna, Daniela, Forcina, Alessandra, Andrea Scelfo, Mori, Lucia, S. Ramanjaneyulu Gundimeda, Chiara Bonini, Claudio Garavaglia, A. Scelfo, Francesco Piccolo, Ni, Guanghui, C. Xia, Dellabona, Paolo, Haussinger D, Xia CF, De Libero G., Ciceri F, Piccolo F, Ni GH, Ni G, de Lalla C, Montagna D, Gundimeda SR, Jeno P, Bonini C, Xia C, Consonni M, Forcina A, Li Z, Bondanza A, Scelfo A, Garavaglia C, Locatelli F, Dellabona P, Casorati G, Mori L, Lepore M, Gsellinger H, De Libero G, Sansano S, Li ZY, BONDANZA , ATTILIO, CICERI , FABIO, BONINI , MARIA CHIARA   +100 more
core   +1 more source

APOBEC3 activity and DNA polymerase‐ε deficiency are associated with distinct IDH1 R132 hotspot mutations

Molecular Oncology, EarlyView.
Isocitrate dehydrogenase 1 (IDH1) mutations are highly recurrent in multiple human cancer types, including cholangiocarcinoma and glioma. IDH1 R132C is the most common IDH1 mutation in cholangiocarcinoma and likely arises from APOBEC3A‐ or APOBEC3B‐mediated deamination.
Kelly E. Butler, Bilal A. Lone, Ecem Unal, A. Rouf Banday   +3 more
wiley   +1 more source